SCHEMBL9508

SCHEMBL9508

O=C(O)c1cnc2ccc(Br)cc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.62
ALPL P05186 2/20 0.49
POLB P06746 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
EGLN1 Q9GZT9 1/20 0.44
PSMD14 O00487 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MALT1 Q9UDY8 1/20 0.41
PTGFR P43088 2/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
P4HA1 P13674 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
PIM1 P11309 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2147076 0.86 MGAM (0.53) MGAMALPLPOLBHCAR2MMP2
SCHEMBL1352602 0.86 MGAM (0.62) MGAMALPLPOLBHCAR2MMP2
SCHEMBL10465639 0.85 MGAM (0.70) MGAMALPLPSMD14ALDH1A1KDM4E
SCHEMBL15775057 0.85 ALPL (0.50) MGAMALPLPSMD14MALT1SMN1; SMN2
SCHEMBL9637 0.85 HTT (0.46) MGAMALPLALDH1A1MALT1HTT
SCHEMBL1681021 0.85 MGAM (0.51) MGAMALPLPOLBHCAR2MMP2
Lithium SCHEMBL1681024 0.85 MGAM (0.51) MGAMALPLPOLBHCAR2MMP2
SCHEMBL16127621 0.85 MGAM (0.44) MGAMALPLMMP2MMP9MMP8
SCHEMBL31347988 0.83 HDAC6 (0.45) MGAMALPLMALT1
SCHEMBL1351061 0.81 HTT (0.52) ALPLMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120887867-B Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof 浙江中医药大学 2026-05-15 CN claimed
CN-120887867-B Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof 浙江中医药大学 2026-05-15 CN disclosed
EP-4709479-A1 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS Amgen Inc. (US) 2026-03-18 EP disclosed
WO-2024233563-A1 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS AMGEN INC. (US) 2024-11-14 WO disclosed
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof MILLENNIUM PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-11547697-B2 Heterocyclic compounds and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2023-01-10 US disclosed
CN-111943957-B Quinoline formamide compound and preparation method and application thereof 中国医学科学院药物研究所 2023-01-06 CN disclosed
CN-109942653-B Erythromycin derivative and preparation method thereof 北京理工大学 2021-06-25 CN disclosed
CN-111943957-A Quinoline formamide compound and preparation method and application thereof 中国医学科学院药物研究所 2020-11-17 CN disclosed
WO-2020205467-A1 STAT3 PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-10-08 WO disclosed
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed
WO-2011146591-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 WO disclosed
WO-2011146591-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 WO disclosed
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed
WO-2011131741-A1 HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-27 WO disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-10-15 US disclosed
CN-101553490-A Bicyclic triazoles as protein kinase modulators SGX PHARMACEUTICALS INC (US) 2009-10-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321050-A1 Heterocyclic Compounds and Uses Thereof PIK3CA, PIK3CD, PIK3CB MGAM 3254/4885ALPL 3852/4885POLB 2432/4885
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD MGAM 431/4885ALPL 440/4885POLB 1098/4885
US-11547697-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB MGAM 3254/4885ALPL 3852/4885POLB 2432/4885
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 MGAM 4458/4885ALPL 4527/4885POLB 438/4885
US-20090258855-A1 BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS MAP3K20, TTK, PRKACB MGAM 4052/4885ALPL 4673/4885POLB 2724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.